Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to compare two ways of giving the anti-cancer medicines abemaciclib and hormone therapy with tersolisib in participants with early breast cancer that has a genetic mutation (PIK3CA mutation). For each participant, the study will last up to 56 weeks and include 12 visits.
Official title: A Phase 2, Open-label, Randomized Study Investigating the Tolerability of Concurrent Versus Staggered Administration of Abemaciclib and Endocrine Therapy With Tersolisib in Patients With HR+, HER2- Node-Positive, PIK3CA-Mutated Early Breast Cancer.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-12
Completion Date
2028-01
Last Updated
2026-11-13
Healthy Volunteers
No
Conditions
Interventions
Abemaciclib
Administered orally
Tersolisib
Administered orally
Letrozole
Administered orally
Anastrozole
Administered orally
Exemestane
Administered orally
Locations (9)
Cancer and Blood Specialty Clinic
Los Alamitos, California, United States
USO - Rocky Mountain Cancer Centers
Lakewood, Colorado, United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio, United States
Texas Oncology - West Texas
Amarillo, Texas, United States
Texas Oncology - Balcones
Austin, Texas, United States
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, United States
USO - Virginia Cancer Specialists
Reston, Virginia, United States